IRIS
TASSONE, PIERFRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.379
AS - Asia 5.216
EU - Europa 2.778
SA - Sud America 1.379
AF - Africa 110
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 19
Totale 15.906
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.060
SG - Singapore 2.348
IT - Italia 1.284
CN - Cina 1.150
BR - Brasile 1.048
VN - Vietnam 619
IN - India 591
SE - Svezia 406
GB - Regno Unito 347
DE - Germania 272
CA - Canada 238
AR - Argentina 120
FI - Finlandia 102
ID - Indonesia 77
HK - Hong Kong 73
EC - Ecuador 67
BD - Bangladesh 57
NL - Olanda 56
MX - Messico 55
RU - Federazione Russa 47
FR - Francia 42
IQ - Iraq 40
CO - Colombia 36
PK - Pakistan 36
RO - Romania 36
ES - Italia 35
UA - Ucraina 33
PY - Paraguay 30
ZA - Sudafrica 30
JO - Giordania 29
JP - Giappone 28
CL - Cile 25
PL - Polonia 23
TR - Turchia 23
EU - Europa 22
EG - Egitto 20
IR - Iran 20
PE - Perù 20
SA - Arabia Saudita 20
VE - Venezuela 20
CZ - Repubblica Ceca 17
LT - Lituania 16
AE - Emirati Arabi Uniti 15
AT - Austria 14
MA - Marocco 13
AU - Australia 12
KR - Corea 11
KE - Kenya 10
TN - Tunisia 10
UZ - Uzbekistan 10
PT - Portogallo 9
UY - Uruguay 9
MY - Malesia 8
ET - Etiopia 7
IE - Irlanda 7
LB - Libano 7
NG - Nigeria 7
BG - Bulgaria 6
DZ - Algeria 6
EE - Estonia 6
GT - Guatemala 6
KZ - Kazakistan 6
CY - Cipro 5
HN - Honduras 5
NP - Nepal 5
AZ - Azerbaigian 4
CH - Svizzera 4
DO - Repubblica Dominicana 4
IL - Israele 4
NZ - Nuova Zelanda 4
PH - Filippine 4
PS - Palestinian Territory 4
SN - Senegal 4
TW - Taiwan 4
BN - Brunei Darussalam 3
HU - Ungheria 3
KG - Kirghizistan 3
LK - Sri Lanka 3
OM - Oman 3
PA - Panama 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
CR - Costa Rica 2
GE - Georgia 2
GR - Grecia 2
GY - Guiana 2
HR - Croazia 2
KI - Kiribati 2
KW - Kuwait 2
AO - Angola 1
BY - Bielorussia 1
CV - Capo Verde 1
DK - Danimarca 1
GM - Gambi 1
JM - Giamaica 1
MD - Moldavia 1
NI - Nicaragua 1
Totale 15.899
Salva come PNG Salva come JPEG
Città #
Chandler 906
Singapore 770
Dallas 505
Santa Clara 457
Bengaluru 428
Hefei 428
Milan 390
Lawrence 383
Princeton 383
Ashburn 337
Chicago 269
London 249
Ho Chi Minh City 241
Wilmington 224
Munich 211
Beijing 189
Ottawa 165
Catanzaro 153
Hanoi 119
Des Moines 111
São Paulo 87
Boardman 85
Turku 73
Los Angeles 69
Hong Kong 61
New York 55
Shanghai 48
Rome 47
Rio de Janeiro 43
Guangzhou 41
Pune 40
Naples 36
The Dalles 34
Norwalk 32
San Francisco 31
Brooklyn 30
Redwood City 30
Haiphong 29
Helsinki 29
Council Bluffs 28
Redmond 28
Da Nang 25
Biên Hòa 24
Montreal 22
Quito 22
Amman 21
Warsaw 21
Chennai 20
Columbus 19
Curitiba 19
Parma 19
San Jose 19
Atlanta 18
Boston 18
Stockholm 18
Thái Bình 18
Phoenix 17
Salvador 17
Manchester 16
San Nicola Manfredi 16
Tokyo 16
Baghdad 15
Denver 15
Guayaquil 15
Charlotte 14
Mexico City 14
Olomouc 14
Porto Alegre 14
Reggio Calabria 14
West Jordan 14
Campinas 13
Delhi 13
Horia 13
Mountain View 13
Amsterdam 12
Brasília 12
Buenos Aires 12
Carbonia 12
Dhaka 12
Johannesburg 12
Palermo 12
Recife 12
Thái Nguyên 12
Timisoara 12
Vallefiorita 12
Washington 12
Augusta 11
Cosenza 11
Hanover 11
Ankara 10
Bari 10
Belo Horizonte 10
Duque de Caxias 10
Guarulhos 10
Jakarta 10
Lima 10
Madrid 10
Nairobi 10
Seattle 10
Tashkent 10
Totale 8.727
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 409
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 118
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 96
miR-22 suppresses DNA ligase III addiction in multiple myeloma 96
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 86
An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity 84
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 79
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 78
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 73
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 72
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 71
A 5 ' regulatory sequence containing two Ets motifs controls the expression of the Wiskott-Aldrich syndrome protein (WASP) gene in human hematopoietic cells 70
Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer 70
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 70
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 69
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 69
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease 68
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 68
Pyrrolo[2′,3′:3,4]cyclohepta[1,2- d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types 68
277 POSTER An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity 67
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 67
Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43 67
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 67
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 65
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 63
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 63
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 63
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 62
Associazione di antagonisti di IL-6 e farmaci anti-proliferativi (depositato il 10.3.2005 n. RM2005A000103) 62
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 62
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 61
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 60
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 60
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 59
A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells 59
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 59
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 59
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 58
Differential microRNAs expression profile in coronary thrombi from patients with no-reflow after primary PCI 58
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 58
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 58
Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs 57
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 57
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 56
Fetal ontogeny and tumor expression of the early thymic antigen UN1 56
Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report 56
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 56
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 56
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 56
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 55
miR-221/222 inhibitors for the treatment of multiple myeloma 55
Mir-34: a new weapon against cancer? 54
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 54
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 54
Oleil hydroxytyrosol (Htol) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells (CO-FIRST AUTHOR) 54
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 53
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 53
Liposomes containing zoledronic acid: A new opportunity against cancer 53
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 53
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 53
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 53
Anti-myeloma activity of miR-125 mimics 53
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 52
Biochemical modification of an Interleukin-6 antagonist to target myeloma cells in the bone marrow microenvironment 52
HLA class I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells 52
PEGylated Aqueous core PLA-nanocapsules as efficacious gene delivery vehicle 52
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 52
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 52
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 51
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 51
Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma 51
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 51
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 50
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 50
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 50
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells 49
[Extended subcutaneous mastectomy. A new type of operation in non-destructive surgery of breast neoplasms]. FT La mastectomia sottocutanea allargata. Un nuovo tipo d'intervento nella chirurgia non demolitiva della neoplasia mammaria. 49
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia 49
Transcriptional regulation of the mismatch repair gene hMLH1 49
Genes specifically expressed during early stages of haemopoietic differentiation detected by DDRT-PCR. 49
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. 49
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 49
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 49
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 49
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 49
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 48
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation 48
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of cancer 48
Modulation of Exosomal microRNA in patients with severe Aortic Stenosis after Transcatheter Aortic Valve Implantation (TAVI) 48
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? 48
Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma 48
[Magnesium salts in the treatment of ventricular tachycardia]. FT I sali di magnesio nel trattamento della tachicardia ventricolare. 48
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 48
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 48
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 48
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 48
Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates 48
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 48
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 47
Mir-221/222 are promising targets for innovative anticancer therapy 47
Totale 6.192
Salva come PNG Salva come JPEG
Categoria #
all - tutte 181.105
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 181.105
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021347 0 0 0 0 0 53 33 26 73 82 65 15
2021/20221.151 27 6 17 333 87 20 29 249 114 97 149 23
2022/20232.838 787 108 110 204 299 234 23 198 425 171 228 51
2023/20241.557 347 158 127 110 104 379 45 61 13 51 65 97
2024/20254.484 615 274 203 134 251 564 126 163 510 266 448 930
2025/20265.341 454 966 1.028 1.709 916 268 0 0 0 0 0 0
Totale 16.237